Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OriC321 in Relapsed or Refractory Multiple Myeloma
NCT05325801Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of OriC321 in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoint: Incidence and severity of Adverse Events and Serious Adverse Events at 2 years. Status: unknown.
02
Drugs
OriC321
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05325801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325801.